Support our projects and causes
Do you want to become a company sponsor?
Meningokockfonden is a foundation that is 100% based on non-profit forces. In order to drive our business forward, we have created an opportunity for companies that want to help us in our work. By becoming the Meningococcal Foundation's Company Sponsor, you contribute to our work to increase awareness of meningococci and to research around the meningococcal bacterium. As a thank you for your support, you / your company will receive: Information material about meningococci in the form of an A3 poster Information material on meningococci in the form of an A5 brochure Information material about meningococci in the form of small business cards with the symptoms Meningokockfonden's pens Digital banner to use on your own website Exposure of your company name and log on to Meningokockfonden's website 10 "Beat Meningitis" bracelet
Information for young people aged 15-24
Why are young people particularly vulnerable? Healthy teens more often have meningococci in their throats than others. In addition, they participate in activities that increase the risk of infection and becoming seriously ill, such as close contact with other young people for several days, partying, high alcohol consumption, sharing bottles and cigarettes, active or passive smoking and a little sleep. This applies especially to the years around the study period, but can also be relevant at festivals, sports gatherings, youth camps, the military and the like. How do you protect yourself? The risk of developing meningococci is reduced if you do not share bottles and glasses with others, get enough sleep, have low alcohol consumption and avoid smoking. As the disease develops very quickly, it is very important to get to the hospital early. Binge drinking, fatigue and meningococcus may have similar symptoms. Contact your healthcare provider if you think any of your friends may be ill, especially if they have impaired consciousness. Trust your instincts! Vaccination It is possible to be vaccinated against meningococci. In many other countries in the world, it is recommended that young people aged 15–24 who participate in activities described here be vaccinated against meningococci. The recommendation also applies to younger and older young people. There are two different types of vaccines. Combination vaccines against meningococcal groups A, C, W and Y protect against these groups of meningococcal bacteria. Vaccine against meningococcus group B is also available. If you want protection against most groups of meningococcal bacteria circulating in Sweden, you should be vaccinated with both. Vaccination against meningococcus A, C, W and Y consists of one dose. Vaccination against meningococcus B consists of two doses. The protection lasts for about 5 years.
We have contributed to a study!
We are proud to announce that, thanks to all the donations that have been received, we have been involved in providing a grant of SEK 50,000 for the start of a study on meningococcal disease in children and adolescents. The purpose of this study is to study in detail all confirmed cases of meningococcal disease in children and adolescents in Sweden between 2000-2022 to: Identify risk factors for developing meningococcal disease in children and adolescents in Sweden, including immunological factors Measure the degree of permanent damage in children and adolescents who have undergone meningococcal disease by measuring physical and cognitive impairment Study complementary function and other immunological parameters that may pose a risk of developing meningococcal disease Study the bacterial strains that cause meningococcal disease at the molecular level Estimate the frequency of meningococcal carriers in healthy children and adolescents Examine factors in the acute care (triage, examination, diagnosis, treatment) of children with meningococcal disease to identify which steps in the acute care that may pose a risk of missing the early diagnosis of meningococcal disease Children, adolescents and young adults are a special risk group for invasive meningococcal disease. Children during the first year of life and adolescents and young adults have the highest incidence in international studies and in national data from the Swedish Public Health Agency. A characteristic of invasive meningococcal disease is the rapid course of the disease, which often leads to a very difficult-to-treat condition for a short time. This places great demands on healthcare efforts to prevent death or permanent injury (sequelae). A lot has been described about these remaining sequelae of meningococcal disease. An important aspect, however, is the geographical differences in both the type of meningococcal bacteria that affect patients and the proportion of meningitis and sepsis, respectively. Therefore, it is of the utmost importance to have national and regional data to lean on in order to be able to correctly assess the need for both preventive, therapeutic and rehabilitation measures in meningococcal disease. Many children and young people with meningococcal disease have been in contact with healthcare in some way the day before the severe illness. This may be medical advice (eg 1177), primary care or emergency room, but has been judged to have problems that did not require urgent treatment. An in-depth understanding of factors leading to delayed diagnosis could increase the quality of emergency care. The description is based on the research plan and the study is based on Karolinska Institutet with several partners.
Our impact map